Aug 10, 2009 - Sepracor Inc. today announced that its Canadian subsidiary, Sepracor Pharmaceuticals, Inc., has submitted an application to the Therapeutic Products Directorate (TPD) of Health Canada for eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.
The details can be read here.
No comments:
Post a Comment